Early-stage biotech Target Exoxemis Inc as a high-potential early-stage biotech customer with limited revenue but ambitious growth. Their focus on enzyme-based pathogen killing suggests opportunities for cost-effective lab tools, contract research services, or scalable digital infrastructure to support R&D pipelines.

R&D tooling Recommend value propositions around scalable computational biology support, data management, and cloud-based collaboration to accelerate research. Their tech stack indicates openness to cloud and web platforms which can be partnered with for data storage, analytics, and compliant collaboration.

Outsourced operations Position services that reduce internal overhead for small teams, such as managed IT, cybersecurity, and compliance consulting, to protect intellectual property given their use of multiple web platforms and growing digital footprint.

Strategic partnerships Leverage connections to look for collaboration or supply partnerships with larger entities in related sectors (biotech, materials science, healthcare) to scale impact, leveraging their minimal headcount to enable efficient joint ventures.

Funding & growth Note their revenue below 1M with a lean team; tailor solutions that maximize ROI, such as affordable cloud services, low-overhead deployment, and scalable e-commerce or grant management tools to support product commercialization as they grow.